Tazarotene NEW
| Price | $32 | $45 | $81 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-08 |
Product Details
| Product Name: Tazarotene | CAS No.: 118292-40-3 |
| Purity: 99.14% | Supply Ability: 10g |
| Release date: 2024/11/08 |
Product Introduction
Bioactivity
| 名稱 | Tazarotene |
| 描述 | Tazarotene (Zorac) is a synthetic, topical retinoid. Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. |
| 體外活性 | Tazarotene causes ERK activation, RB tumor suppressor protein hypophosphorylation, G0 arrest, and myeloid differentiation in HL-60 human myeloblastic leukemia cells. Tazarotene could propel either early or late portions of the period leading to differentiation and G0 arrest and is interchangeable with an RARalpha-selective ligand. [1] Tazarotene therapy regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis. [2] Tazarotene inhibits the proliferation of fibroblasts and synthesis of DNA and collagen. [3] Tazarotene down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. Tazarotene also up-regulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect. [4] Tazarotene causes growth suppression in retinoid-responsive breast cancer cell lines by up-regulating TIG3. [5] |
| 體內(nèi)活性 | Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in UV-treated Ptch1+/? mice. Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in ionizing radiation-treated Ptch1+/? mice. [5] |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 16.67 mg/mL (47.42 mM), Sonication is recommended. Ethanol : 17.6 mg/mL (50 mM) |
| 關(guān)鍵字 | inhibit | Inhibitor | RAR/RXR | Retinoic acid receptors | Autophagy | AGN-190168 | Tazarotene | AGN190168 | Retinoid X receptors |
| 相關(guān)產(chǎn)品 | Hydroxychloroquine | Guanidine hydrochloride |
| 相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌臨床化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌上市藥物庫(kù) | 抗癌藥物庫(kù) | 抗癌活性化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $10.00/1kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-29 | ||
| $3.00/1kg |
VIP1Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-16 | |
| $50.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-08-10 | ||
| $0.00/1KG |
VIP2Y
|
Wuhan Haorong Biotechnology Co.,Ltd
|
2023-07-31 | |
| $0.00/1KG |
Hubei Harvest Chemical CO.,Ltd
|
2022-12-20 | ||
| $0.00/25Kg/Drum |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2022-07-06 | |
| $1.20/1g |
Qiuxian Baitai New Material Co., LTD
|
2021-11-26 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-08 | ||
| $0.00/1g/Bag |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-07-03 | |
| $80.00/1g |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-08 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY